Kelsey Pan: Happy to share our analysis of NSCLC patients with germline EGFR mutations
Kelsey Pan, Heme/Onc Chief Fellow at MD Anderson Cancer Center, shared a post by Stephen V Liu, on X:
“Happy to share our institutional analysis of NSCLC patients with germline EGFR mutations in JTO and JTO CRR with Xiuning Le.
- Majority Caucasian, non-smoking, females, with family history of lung cancer
- 21/22 with ‘second-hit’ EGFR somatic co-mutation (L858R in 50%). Tp53 co-mutation in 50%
- Small multifocal ground glass nodules (73%)
- Similar response to Osimertinib as somatic EGFRm population.“
Quoting Stephen V Liu‘s post:
“Description of NSCLC with germline EGFR mutations (mostly T790M) from Dr. Kelsey Pan JTO and JTO CRR (n=22). 86% female, 82% no smoking history, 59% +family history, 73% with multifocal ground glass pulmonary nodules. Respond as expected to osimertinib.”
Read further.
Source: Kelsey Pan/X and Stephen V Liu/X
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.
His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.